Manulife Financial Corporation ("Manulife" or the "Company") reported its third quarter results for the period ended September 30, 2025, delivering record core earnings and double-digit growth in core ...
Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback